Sherman Spotlights Advances With RET Inhibitors in Medullary Thyroid Cancer

Partner | Cancer Centers | <b>Memorial Sloan Kettering Cancer Center </b>

Dr. Sherman discusses the incidence of RET fusions in medullary thyroid cancer and the current clinical landscape of RET inhibitors in the field.

Welcome to OncLive On Air®! I’m your host today, Jessica Hergert.

OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, sponsored by Eli Lilly and Company, we had the pleasure of speaking with Eric J. Sherman, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, to discuss the prognosis of patients with RET fusion–positive medullary thyroid cancer, the data supporting the regulatory approvals of selpercatinib (Retevmo) and pralsetinib (Gavreto), and future research directions with RET inhibitors in the field.

In our exclusive interview, Sherman discussed the incidence of RET fusions in medullary thyroid cancer and the current clinical landscape of RET inhibitors in the field.